Portage biotech resumes enrollment in final cohort of dose escalation for port-6 in adport-601 trial

Encouraging safety profile supports progression toward first dual-administration of selective a2a and a2b antagonists in patients encouraging safety profile supports progression toward first dual-administration of selective a2a and a2b antagonists in patients
ATON Ratings Summary
ATON Quant Ranking